All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, August 14, 2022
Home » Blogs » BioWorld Perspectives » The Biogodess: Chief Executive of Biotech Industry Nurturing

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld

The Biogodess: Chief Executive of Biotech Industry Nurturing

Sep. 6, 2011
By Lynn Yoffee
No Comments

She’s best known as the Biogodess. A biotech insider who can recount the early days in the sector -- when the industry was first starting to attract serious biobucks. The Biogodess has helped many bridge the gap of knowledge between the science and business of this Wild West of the pharmaceutical industry. She’s tracked the sector’s roller coaster ride like few others. In the early days of the male-dominated industry, it was pretty easy to spot her in a crowd. Not just because she was a woman, but because she had a bright and effervescent fashion sense in a sea of dark suits. And a serious thing going on with knock-out shoes.

Over the years, the Biogodess has advised international venture capital firms, helped to establish biotech companies, wrote two books (Alternative Careers in Science: Leaving the Ivory Tower and From Alchemy To IPO: The Business Of Biotechnology) and much more. She’s a biotech veteran who helped nurture the industry from a variety of angles.

AKA Cynthia Robbins-Roth, the Biogodess has also been a BioWorld Today columnist (Fun With Finances), author of BioWorld Perspectives’ “All My Clones” soap opera (along with some longtime, anonymous collaborators) and BioWorld Bytes – Cranky Commentary. She’s been a key figure to BioWorld for almost two decades.

BioWorld’s publisher, Donald R. Johnston, told me that when our company began due diligence to acquire BioWorld from Io Publishing Inc. in 1994, Cindy promptly called him with a lunch invitation during his first visit to the San Mateo, Calif. office. Cindy was BioWorld’s founding editor in chief, but by that time, she had already moved back to the businesses she started in 1986: BioVenture Publishing and BioVenture Consultants. Don and Cindy have been great friends ever since.

The former Genentech Inc. scientist has had an amazing career and, although we’ve published the last episode of “All My Clones” and are discontinuing BioWorld Bytes (in part because of the buzz created by this blog), Cindy will remain on board to provide us with her lively insight assessing quarterly private biotech financings in her Fun With Finances column. And maybe more?

Though she continues her biotech consulting and writing, Cindy had a life-changing experience a decade ago. She survived a plane crash, which sent her in a different career direction. She’s now occupied as a family partner at Edgewood Center’s Turning Point Program, in California, working with young adults facing the challenges of serious mental health disabilities, and their families. Three cheers for the Biogodess for taking on such a commendable challenge, particularly in a state with no money!

So, rather than a quick editor’s note to let you know that we are retiring those two columns, I wanted to take the opportunity to pay tribute to this woman who was and remains so important to BioWorld. She’s a true biotech icon. Thank you, Cindy.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld
    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Aug. 12, 2022.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Aug. 12, 2022.
  • Amvuttra

    Alnylam’s Amvuttra rare disease drug among positive recommendations from Europe’s CHMP

    BioWorld
    Alnylam Pharmaceuticals Inc.’s Amvuttra (vutrisiran), a treatment for the rare disease hereditary transthyretin-mediated amyloidosis, was among medicines...
  • Pig organ cells

    Whole body cellular function recovery in pigs after death

    Science
    A new system for restoring cell function and tissues in mammals after death could expand the availability of organs for transplantation. The research also opens...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing